New York, USA, June 26, 2023 (GLOBE NEWSWIRE) -- Hepatocellular Carcinoma Clinical Trial Analysis: DelveInsight Evaluates a Robust Pipeline as 90+ Influential Pharma Players to Set Foot in the Domain
The increase in the prevalence of Hepatocellular Carcinoma has been marked as the second leading cause of death after cardiovascular diseases. Environmental factors such as alcohol consumption, smoking, and increasing urbanization are the main causes of its prevalence. Thus, a higher prevalence and demand for effective drugs are anticipated to drive the market’s growth.
DelveInsight’s 'Hepatocellular Carcinoma Pipeline Insight 2023' report provides comprehensive global coverage of pipeline hepatocellular carcinoma therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the hepatocellular carcinoma pipeline domain.
Key Takeaways from the Hepatocellular Carcinoma Pipeline Report
- DelveInsight’s hepatocellular carcinoma pipeline report depicts a robust space with 90+ active players working to develop 95+ pipeline therapies for hepatocellular carcinoma treatment.
- Key hepatocellular carcinoma companies such as Can-Fite BioPharma, Sinocelltech, AVEO Oncology, Oxford BioTherapeutics, Beijing SyngenTech, Surface Oncology, Novartis Oncology, Array BioPharma, Taizhou Hanzhong Pharmaceuticals, Akeso Biopharma, Shanghai Henlius Biotech, Chugai Pharmaceutical, CStone Pharmaceuticals, Shenogen Pharma, GlaxoSmithKline, Tarus Therapeutics, Tvardi Therapeutics, Virogin Biotech, Yiviva, Chia Tai Tianqing Pharmaceutical Group, Antengene Corporation, Iterion Therapeutics, Sumitomo Pharma, SillaJen Biotherapeutics, SCG Cell Therapy, Guangdong ProCapZoom Biosciences, Eutilex, Polaris Pharmaceuticals, OriCell Therapeutics, Gongwin Biopharm, Celgene Corporation, Phanes Therapeutics, MacroGenics, Genoscience Pharma, Tempest Therapeutics, JW Therapeutics, NETRIS Pharma, Adagene, and others are evaluating new hepatocellular carcinoma drugs to improve the treatment landscape.
- Promising hepatocellular carcinoma pipeline therapies such as Namodenoson, Tivozanib, SCT-I10A, OBT-624, SynOV1.1, SRF388, INC280, HX008, AK104, Serplulimab, ERY974, Fisogatinib, Icaritin, TSR-022, TT-4, TTI-101, VG161, YIV-906, TQB2450, ATG 008, BBI608, Tegavivint, Pexastimogene Devacirepvec, SCG101, SZ003, EU307, ADI-PEG20, Ori-C101, Para-Toluenesulfonamide, CC-122, PT199, vobramitamab duocarmazine, ezurpimtrostat, TPST-1120, JWATM214, NP137, ADG126, and others are under different phases of hepatocellular carcinoma clinical trials.
- In May 2023, Harbour BioMed announced the results of the phase Ib clinical trial of porustobart (HBM4003), in combination of toripalimab in patients with hepatocellular carcinoma (HCC) (trial code: NCT05149027) were released at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023.
- In April 2023, Tempest Therapeutics announced positive early results from a global randomized Phase Ib/II clinical study in which TPST-1120, Tempest’s small molecule PPAR⍺ antagonist, demonstrated clinically-meaningful improvement in multiple categories when combined with the standard-of-care regimen of atezolizumab and bevacizumab in a randomized comparison to atezolizumab and bevacizumab in the first-line treatment of patients with unresectable or metastatic hepatocellular carcinoma (HCC).
- In March 2023, Omega Therapeutics announced a clinical supply agreement with Roche to evaluate OTX-2002, its lead candidate in development for the treatment of MYC-driven hepatocellular carcinoma (HCC), in combination with Roche’s anti-PD-L1 therapy, atezolizumab, as part of Omega’s Phase I/II MYCHELANGELO clinical trial.
- In February 2023, JW Therapeutics announced the initiation of clinical study of JWATM214 in patients with advanced hepatocellular carcinoma (HCC) and the first patient infusion. This first-in-human study of JWATM214 aims to evaluate the safety and tolerability, determine the recommended phase II dose (RP2D), and evaluate the pharmacokinetic profile and preliminary efficacy of JWATM214 in adult patients with GPC-3-expressing advanced HCC.
- In February 2023, Genoscience Pharma announced that its lead candidate, ezurpimtrostat, a PPT-1 (Palmitoyl Protein Thioesterase-1) inhibitor, had been granted Orphan Drug Designation (ODD) by the US Food and Drug Administration (FDA) for the treatment of Hepatocellular Carcinoma (HCC).
- In January 2023, NETRIS Pharma announced dosing of the first patients in a multicenter, prospective, single-arm, proof-of-concept trial of the anti-netrin-1 antibody, NP137, in combination with atezolizumab-bevacizumab (Atezo-bev) in first-line patients with advanced hepatocellular carcinoma.
- In December 2022, Adagene announced a clinical trial collaboration with Roche to evaluate the triple combination of Adagene’s ADG126 with Roche’s atezolizumab and bevacizumab in first-line treatment of advanced hepatocellular carcinoma (HCC; liver cancer). The collaboration will utilize Roche’s MORPHEUS-LIVER platform for rapid and efficient combination development.
- In November 2022, the FDA had granted an orphan drug designation to OTX-2002, a first-in-class epigenomic controller engineered to downregulate c-Myc (MYC), for the treatment of patients with hepatocellular carcinoma (HCC), according to an announcement from the drug developer, Omega Therapeutics.
Request a sample and discover the recent advances in hepatocellular carcinoma treatment drugs @ Hepatocellular Carcinoma Pipeline Report
The hepatocellular carcinoma pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage hepatocellular carcinoma drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the hepatocellular carcinoma clinical trial landscape.
Hepatocellular Carcinoma Overview
Hepatocellular carcinoma is a rare disease in the United States, yet it is the most frequent primary liver tumor. Most people have underlying liver disease, such as hepatitis B or C virus infection or non-alcoholic fatty liver disease. Cirrhosis, or scarring of the liver caused by chronic liver diseases, affects the majority of people. If hepatocellular carcinoma is detected early, curative treatments may be available. However, hepatocellular carcinoma does not always induce symptoms, especially early in the disease’s progression. If hepatocellular carcinoma is detected at a late stage, patients may not be able to obtain curative treatments, and care is then aimed toward improving people’s quality of life.
Although hepatocellular carcinoma does not always induce symptoms, many people experience symptoms as a result of the underlying liver disease. The cause of hepatocellular carcinoma is not completely understood. The majority of patients have no visible signs of hepatocellular carcinoma. They may develop symptoms of liver cirrhosis that are difficult to manage. The liver may become decompensated as a result of the underlying liver disease and hepatocellular carcinoma. This indicates that an organ, in this case, the liver, is having difficulty correcting for disease consequences.
Find out more about hepatocellular carcinoma treatment drugs @ Drugs for Hepatocellular Carcinoma Treatment
A snapshot of the Hepatocellular Carcinoma Pipeline Drugs mentioned in the report:
| Drugs | Company | Phase | MoA | RoA |
| Namodenoson | Can-Fite BioPharma | Phase III | Adenosine A3 receptor agonist; Hepatitis C virus NS 5 protein inhibitor | Oral |
| SCT-I10A | Sinocelltech | Phase II/III | Antibody-dependent cell cytotoxicity; Programmed cell death-1 receptor antagonists; T lymphocyte stimulants | Intravenous |
| SRF388 | Surface Oncology | Phase II | Immunosuppressive cytokine inhibitor | Intravenous |
| Capmatinib | Novartis Oncology | Phase II | Proto oncogene protein c met inhibitors | Oral |
| Fisogatinib | CStone Pharmaceuticals | Phase I/II | Type 4 fibroblast growth factor receptor antagonists | Oral |
| Tivozanib | AVEO Oncology | Phase I/II | Protein tyrosine kinase inhibitors; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists | Oral |
| ERY974 | Chugai Pharmaceutical | Phase I | Antibody-dependent cell cytotoxicity; T lymphocyte stimulants | Intravenous |
Learn more about the emerging hepatocellular carcinoma pipeline therapies @ Hepatocellular Carcinoma Clinical Trials
Hepatocellular Carcinoma Therapeutics Assessment
The hepatocellular carcinoma pipeline report proffers an integral view of the hepatocellular carcinoma emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.
Scope of the Hepatocellular Carcinoma Pipeline Report
- Coverage: Global
- Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
- Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Therapeutics Assessment By Route of Administration: Intra-articular, Intraocular, Intrathecal, Intravenous, Ophthalmic, Oral, Parenteral, Subcutaneous, Topical, Transdermal
- Therapeutics Assessment By Molecule Type: Oligonucleotide, Peptide, Small molecule
- Therapeutics Assessment By Mechanism of Action: Adenosine A3 receptor agonists Hepatitis C virus NS 5 protein inhibitor, Protein tyrosine kinase inhibitors, Vascular endothelial growth factor receptor 3 antagonists, Vascular endothelial growth factor receptor-1 antagonists, Vascular endothelial growth factor receptor-2 antagonists, Antibody-dependent cell cytotoxicity, Programmed cell death-1 receptor antagonists, T lymphocyte stimulants, Proto oncogene protein c met inhibitors, Type 4 fibroblast growth factor receptor antagonists
- Key Hepatocellular Carcinoma Companies: Can-Fite BioPharma, Sinocelltech, AVEO Oncology, Oxford BioTherapeutics, Beijing SyngenTech, Surface Oncology, Novartis Oncology, Array BioPharma, Taizhou Hanzhong Pharmaceuticals, Akeso Biopharma, Shanghai Henlius Biotech, Chugai Pharmaceutical, CStone Pharmaceuticals, Shenogen Pharma, GlaxoSmithKline, Tarus Therapeutics, Tvardi Therapeutics, Virogin Biotech, Yiviva, Chia Tai Tianqing Pharmaceutical Group, Antengene Corporation, Iterion Therapeutics, Sumitomo Pharma, SillaJen Biotherapeutics, SCG Cell Therapy, Guangdong ProCapZoom Biosciences, Eutilex, Polaris Pharmaceuticals, OriCell Therapeutics, Gongwin Biopharm, Celgene Corporation, Phanes Therapeutics, MacroGenics, Genoscience Pharma, Tempest Therapeutics, JW Therapeutics, NETRIS Pharma, Adagene, and others
- Key Hepatocellular Carcinoma Pipeline Therapies: Namodenoson, Tivozanib, SCT-I10A, OBT-624, SynOV1.1, SRF388, INC280, HX008, AK104, Serplulimab, ERY974, Fisogatinib, Icaritin, TSR-022, TT-4, TTI-101, VG161, YIV-906, TQB2450, ATG 008, BBI608, Tegavivint, Pexastimogene Devacirepvec, SCG101, SZ003, EU307, ADI-PEG20, Ori-C101, Para-Toluenesulfonamide, CC-122, PT199, vobramitamab duocarmazine, ezurpimtrostat, TPST-1120, JWATM214, NP137, ADG126, and others
Dive deep into rich insights for new drugs for hepatocellular carcinoma treatment, visit @ Hepatocellular Carcinoma Drugs
Table of Contents
| 1. | Hepatocellular Carcinoma Pipeline Report Introduction |
| 2. | Hepatocellular Carcinoma Pipeline Report Executive Summary |
| 3. | Hepatocellular Carcinoma Pipeline: Overview |
| 4. | Analytical Perspective In-depth Commercial Assessment |
| 5. | Hepatocellular Carcinoma Clinical Trial Therapeutics |
| 6. | Hepatocellular Carcinoma Pipeline: Late-Stage Products (Pre-registration) |
| 7. | Hepatocellular Carcinoma Pipeline: Late-Stage Products (Phase III) |
| 8. | Hepatocellular Carcinoma Pipeline: Mid-Stage Products (Phase II) |
| 9. | Hepatocellular Carcinoma Pipeline: Early-Stage Products (Phase I) |
| 10. | Hepatocellular Carcinoma Pipeline Therapeutics Assessment |
| 11. | Inactive Products in the Hepatocellular Carcinoma Pipeline |
| 12. | Company-University Collaborations (Licensing/Partnering) Analysis |
| 13. | Key Companies |
| 14. | Key Products in the Hepatocellular Carcinoma Pipeline |
| 15. | Unmet Needs |
| 16. | Market Drivers and Barriers |
| 17. | Future Perspectives and Conclusion |
| 18. | Analyst Views |
| 19. | Appendix |
For further information on the hepatocellular carcinoma pipeline therapeutics, reach out @ Hepatocellular Carcinoma Treatment Drugs
Related Reports
Hepatocellular Carcinoma Epidemiology
Hepatocellular Carcinoma Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the hepatocellular carcinoma epidemiology trends.
Hepatocellular Carcinoma Market
Hepatocellular Carcinoma Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key hepatocellular carcinoma companies, including Surface Oncology, Novartis Oncology, Array BioPharma, Taizhou Hanzhong Pharmaceuticals, Akeso Biopharma, Innovent Biologics, Eli Lilly and Company, Shanghai Henlius Biotech, Chugai Pharmaceutical, CStone Pharmaceuticals, among others.
Metastatic Hepatocellular Carcinoma Market
Metastatic Hepatocellular Carcinoma Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key metastatic hepatocellular carcinoma companies, including BeiGene, Zai Lab (Shanghai) Co., Geneos Therapeutics, Adaptimmune Therapeutics, among others.
Metastatic Hepatocellular Carcinoma Pipeline
Metastatic Hepatocellular Carcinoma Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key metastatic hepatocellular carcinoma companies, including BeiGene, Zai Lab (Shanghai) Co., Geneos Therapeutics, Adaptimmune Therapeutics, among others.
Advanced Hepatocellular Carcinoma Pipeline
Advanced Hepatocellular Carcinoma Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key advanced hepatocellular carcinoma companies, including CStone Pharmaceuticals, TaiRx, Yiviva, AVEO Oncology, Eureka Therapeutics, Shanghai Henlius Biotech, Innovent Biologics, Akesobio, among others.
Advanced Hepatocellular Carcinoma with CPB Liver Cirrhosis Pipeline
Advanced Hepatocellular Carcinoma with CPB Liver Cirrhosis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key advanced hepatocellular carcinoma with CPB liver cirrhosis companies, including Can-Fite Biopharma, among others.
Other Trending Reports
Alopecia Market | Invasive Candidiasis Market | Bronchial Spasm Market | Chronic Gout Market | Hpv-Induced Cancers Market | Meningioma Market | Lewy Body Dementia Market | Anti-Gbm Disease Market | Colorectal Cancer CRC Market | Cervical Intraepithelial Neoplasia Market | Carpal Tunnel Syndrome Market | Nonalcoholic Steatohepatitis Market | AIDS Related Kaposis Sarcoma Market | Progressive Supranuclear Palsy Market | Tropical Spastic Paraparesis Market | Secondary Progressive Multiple Sclerosis SPMS Market | Systemic Sclerosis-Associated Interstitial Lung Disease Market | Reactive Airway Disease Market | Ptosis Market | AL Amyloidosis Market | Abdominal Aortic Aneurysm Market | X-Linked Retinitis Pigmentosa Market
Related Healthcare Services
Healthcare Competitive Intelligence Services
Healthcare Asset Prioritization Services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.
Connect with us at LinkedIn
